Healthcare / BiotechnologyShanghai
$13.27
+0.12 (+0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $344.7M · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.2B
P/E
15.8x
↓EV/EBITDA
10.1x
↓ROE
9.9%
↑Gross Margin
67.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.7%
FCF CAGR
+2.4%
FCF margin
36.3%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $949.7M · net income $418.7M · FCF $344.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $949.7M | $949.7M | $941.9M | $1.06B | $1.00B |
| Net Income | $418.7M | $418.7M | $382.4M | $395.9M | $409.5M |
| EBITDA | $593.0M | $593.0M | $552.4M | $580.0M | $569.7M |
| EPS | 0.90 | 0.90 | 0.82 | 0.85 | 0.88 |
| Gross Margin | 67.0% | 67.0% | 63.8% | 72.1% | 73.6% |
| Operating Margin | 40.9% | 40.9% | 39.0% | 45.1% | 42.6% |
| Net Margin | 44.1% | 44.1% | 40.6% | 37.2% | 40.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Current Ratio | 7.42 | 7.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $344.7M | $344.7M | $285.7M | $433.5M | $320.9M |
| Returns | |||||
| ROE | 9.9% | 9.9% | 9.7% | 10.3% | 11.7% |
| Valuation | |||||
| P/E | 15.80 | 15.80 | 16.43 | 23.11 | 24.65 |
| EV/EBITDA | 10.12 | 10.12 | 10.40 | 15.28 | 17.41 |
| P/B | 1.46 | 1.46 | 1.59 | 2.39 | 2.89 |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | -11.5% | 6.3% | — |
| EPS Growth | 9.8% | 9.8% | -3.5% | -3.4% | — |
| Dividend Yield | 4.8% | 4.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.4%
EPS terminal req.
$1.18
Spread vs growth
0.4%
5Y implied EPS CAGR
9.6%
EPS terminal req.
$1.42
Spread vs growth
0.1%
10Y implied EPS CAGR
9.8%
EPS terminal req.
$2.29
Spread vs growth
-0.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.5%
Start / end P/E
21.1x → 14.7x
EPS bridge
0.82 → 0.90
Residual
-2.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.